Fulvestrant: pharmacokinetics and pharmacology.

Article Details

Citation

Copy to clipboard

Robertson JF, Harrison M

Fulvestrant: pharmacokinetics and pharmacology.

Br J Cancer. 2004 Mar;90 Suppl 1:S7-10. doi: 10.1038/sj.bjc.6601630.

PubMed ID

15094758 [ View in PubMed

]

Abstract

Fulvestrant is a new type of oestrogen receptor (ER) antagonist with no agonist activity and a novel pharmacological profile. Fulvestrant has been shown to significantly reduce cellular levels of the ER and progesterone receptor in both preclinical studies and in clinical trials of postmenopausal women with primary breast cancer. This paper reviews the pharmacokinetics and metabolism of fulvestrant, which support the rationale for drug delivery as a single, once-monthly intramuscular injection, and show that this agent has minimal potential to be the subject, or cause, of significant cytochrome p450-mediated drug interactions.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Fulvestrant	Cytochrome P450 3A4	Protein	Humans	Unknown	Substrate	Details